1. Spain Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Pangaea Oncology SA

Pangaea Oncology SA

BBME:PANG
1.43
EUR
0.00
(0.00%)
62.13MMarket Cap
Mar 03Next Earn
Pangaea Oncology SA
BME:PANG
(Spanish Stock Exchange)

Recent

price

1.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.29
0.16
0.18
0.23
0.24
0.23
0.19
0.22
0.2
0.14
0.25
0.42
0.4
- -
Revenue per Share
0.01
-0.02
-0.05
-0.06
-0.15
-0.09
-0.28
-0.09
-0.03
-0.09
-0.15
-0.03
-0.1
- -
Basic EPS, GAAP
-0.07
-0.18
-0.24
-0.22
-0.62
-0.16
-0.14
-0.1
-0.11
-0.12
-0.09
-0.15
-0.08
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.17
0.15
0.1
0.56
0.47
0.64
0.49
0.44
0.62
0.75
0.6
0.65
0.59
0.59
Book Value per Share
-0.26
-0.34
-0.51
-0.2
-0.46
-0.13
0.07
0.07
0.25
0.42
0.09
0.2
0.18
0.18
Tangible Book Value per Share
11
11
11
11
11
13
17
19
23
30
30
34
36
35
Basic Weighted Avg Shares
3
2
2
3
3
3
3
4
5
4
7
14
15
- -
Sales/Revenue/Turnover
6.8
-61.97
-15.21
-59.1
-99.23
-63.64
-69.22
-37.77
-6.46
-50.31
-32.63
-13.98
-25.06
- -
Operating Margin (%)
- -
1
1
1
2
3
3
2
1
1
2
3
3
- -
Depreciation Expense
- -
- -
- -
-1
-2
-1
-5
-2
-1
-3
-5
-1
-4
- -
Net Income, GAAP
55.86
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
2.51
-11.44
-24.95
-23.61
-62.82
-40.96
-145.96
-42.74
-13.94
-62.09
-60.97
-8.18
-24.76
- -
Profit Margin (%)
-1
-2
-1
1
-1
- -
- -
1
4
11
3
6
6
6
Working Capital
1
- -
3
7
2
2
3
4
3
2
2
2
2
2
LT Debt
2
2
1
6
5
9
8
8
14
23
19
23
22
22
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-11.37
-36.27
-16.75
-29.69
-18.49
-57.57
-21.09
-5.73
-14.67
-22.04
-5.82
-16.57
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
4
3
4
LT Borrowings
2
2
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
36
Market Capitalization
60
58
62

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
13
10
13
Cash, Cash Equivalents & STI
4
2
3
Accounts Receivable, Net
7
7
7
Inventories
- -
- -
- -
Total Current Liabilities
7
6
7
Payables & Accruals
- -
- -
- -
ST Debt
4
3
4
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
65.69%
26.63%
-3.41%
Free Cash Flow
19.59%
18.84%
-41.15%
Net Income, GAAP
85.73%
91.88%
208.26%
Sales/Revenue/Turnover
25.32%
34.25%
1.78%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
7
2024
- -
- -
14
2025
- -
- -
15

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.15
2024
- -
- -
-0.03
2025
- -
- -
-0.1

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Pangaea Oncology, S.A. (PANG.MC) operates as a precision oncology company that delivers molecular diagnostics, clinical care, and research and development services to cancer patients and pharmaceutical clients across Spain and the European Union; core offerings encompass mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, gene expression profiling, liquid biopsy predictive models, massive sequencing, in vitro drug profiling including MTT proliferation assays and colony formation tests, biomarker discovery for targeted therapies, companion diagnostic platform validation, clinical trials support, and medical oncology services through subsidiaries such as Instituto Oncológico Dr. Rosell (IOR), International Breast Cancer Center, and Pangaea Lab. The company maintains a state-of-the-art laboratory for pre-treatment services, diagnostic consultancy, and preclinical R&D tools, while its clinical division provides personalized treatment at hospitals within the Quirónsalud Group in Catalonia, positioning it as a Southern European leader in integrating disruptive technologies like AI, big data, and intelligent IT systems. Founded in 2006 and headquartered at Sabino Arana 5-19 in Barcelona, Spain, Pangaea segments operations into clinical care and diagnostic/R&D services, targeting oncology patients, biotech firms, and over 15 multinational pharmaceutical clients with approximately 149 employees. Recent developments include full integration of 2023 acquisitions such as the International Oncology Breast Center (IOB) and Pectus, alongside divestment of Quenet Torrent Institute (QTI), expanding to eight hospitals and driving first-half 2024 revenue to EUR 6.5 million with doubled patient visits and tripled acts; a August 2024 capital increase raised approximately EUR 6.4 million to fund further M&A in diagnostics, alongside new collaborations with SMED Clinical Research for AI-powered trial design and oncology innovation.